期刊文献+

p53在乳腺癌中的表达及其临床意义 被引量:8

The expression of p53 in breast cancer and its clinical significance
下载PDF
导出
摘要 目的探讨p53蛋白在乳腺癌中的表达及其临床意义。方法收集该科收治的214例乳腺癌患者的临床病理资料,回顾性分析p53蛋白表达情况及其与临床病理特征的相关性。结果 p53蛋白阳性率为52.3%;p53阳性表达与患病年龄、病灶大小无相关性(P>0.05),与淋巴结转移状态、肿瘤组织学分级及分子分型呈正相关(r=0.396、0.309、0.167,P=0.000、0.000、0.014),与雌激素受体、孕激素受体的表达呈负相关(r=-0.561、-0.315,P=0.000、0.000),与人表皮生长因子受体2及Ki-67的表达呈正相关(r=0.374、0.153,P=0.000、0.026);三阴型与非三阴型中p53蛋白表达差异有统计学意义(P<0.05)。结论p53与乳腺癌生物学特性密切相关,检测乳腺癌中p53的表达可作为指导临床治疗和判断预后的参考指标。 Objective To investigate the expression of p53 in breast cancer and its clinical significance .Methods The clinical pathological data of 214 cases of breast cancer patients were collected ,and retrospective analyzed of p53 protein expression and its correlation with clinical pathological features .Results The positive rate of p53 was 52 .3% .The expression p53 was no correlation with age ,the size of the lesion(P&gt; 0 .05) ,it was correlation with lymph node metastasis ,histological classification and molecular subtype(r=0 .396 ,0 .309 ,0 .167 ,P=0 .000 ,0 .000 ,0 .014) ,and also have negative correlation with the expression rate of ER ,PR (r= -0 .561 ,-0 .315 ,P=0 .000 ,0 .000) ,positive correlation with HER2 and Ki67(r=0 .374 ,0 .153 ,P=0 .000 ,0 .026) .In the group of triple negative breast cancer (TNBC) and the group of non-TNBC ,the difference was statistically significant of expression of p53 (P&lt;0 .05) .Conclusion p53 protein has closely related with the development ,relapse and metastases of breast cancer ,the detection of p53 can be used to guide the individualized therapy and as a reference index to evaluate the prognosis of breast cancer .
出处 《重庆医学》 CAS CSCD 北大核心 2014年第9期1069-1071,共3页 Chongqing medicine
基金 国家临床重点专科建设资助项目
关键词 基因 p53 乳腺肿瘤 预后 genes p53 breast neoplasms prognosis
  • 相关文献

参考文献21

  • 1Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consen-sus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol,2011,22(8) : 1736-1747.
  • 2Thompson AM, Lane DP. p53 transcriptional pathways in breast cancer: the good, the bad and the complex[J]. J Pathol,2010,220(4) :401-403.
  • 3Fernandez-Cuesta L, Anaganti S, Hainaut P, et al. Estro- gen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines[J]. Breast Cancer Res Treat, 2011,125 (1) : 35-42.
  • 4包刚,杨德启,周波,刘鹏,王殊,程琳.新辅助化疗对乳腺癌组织中雌激素、孕激素受体及P53和CerbB-2表达的影响[J].中华医学杂志,2007,87(40):2843-2845. 被引量:36
  • 5Poelman SM, Heimann R, Fleming GF, et al. Invariant p53 immunostaining in primary and recurrent breast cancer[J]. Eur J Cancer,2004,40(1) :28-32.
  • 6Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and out comes in women with metastatic disease: results from CALGB 9342[J]. Breast Cancer Res,2006,8(6);R66.
  • 7Sidoni A, Cavaliere A, Bellezza G, et al. Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profile [J]. Tumori, 2006,92(5) ;412-415.
  • 8Davidoff AM, Herndon JN,Glover NS,et al. Relation be- tween p53 overexpression and established prognostic fac tors in breast cancer[J]. Surgery, 1991,110(2) : 259-264.
  • 9Auriemma A. Invasive breast cancer: Ki-67 evaluation in 3909 early breast cancer patients[J]. ASCO, 2005,23 ( 16 suppl) .. 678.
  • 10仇加高.乳腺浸润性导管癌中p53和表皮生长因子受体的表达及其意义[J].实用癌症杂志,2013,28(1):31-33. 被引量:5

二级参考文献41

共引文献75

同被引文献74

  • 1李玺,姜华,郭卫平,邱万寿,黄勇,吴珏堃,刘瑞磊,黄泽楠,刘仁斌.卡培他滨引起的手足综合征发病特点与治疗观察[J].中华临床医师杂志(电子版),2011,5(6):1781-1783. 被引量:19
  • 2隆仙琴,林红军,武心萍,李杰,丁文波,王玉国.常规超声联合实时组织弹性成像对浆细胞性乳腺炎的诊断[J].医学研究生学报,2011,24(11):1148-1152. 被引量:11
  • 3周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,1998.331.
  • 4孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.
  • 5Weigel MT, Dowsett M. Current and emerging hiomark- ers in breast cancer: prognosis and prediction[J]. Endocr Relat Cancer, 2010,17(4) : 245-262.
  • 6Ishihara M, Mukai H, Nagai S, et al. Retrospective analy- sis of risk factors for central nervous systemmetastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival [J ]. Oncology, 2013, 84 (3) :135-140.
  • 7Han JG, Jiang YD, Zhang GH, et al. Clinicopathologic characteristics and prognosis of young patients with breast cancer[J]. Breast,2011,20(4) :370-372.
  • 8Fasanella S, Leonardi E, Cantaloni C, et al. Proliferative activity in human breast cancer: Ki-67 automated evalua- tion and the influence of different Ki-67 equivalent anti- bodies[J]. Diagn Pathol, 2011,6 (Suppl 1 ) :S7.
  • 9Goldhirsch A,Wood WC,Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer:high- lights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011,22 (8) : 1736-1747.
  • 10Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplifica- tion of the HER 2/neu on-cogene[J]. Science, 1987,235 (4785) :177-182.

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部